Sale of Cross-Shareholdings and Expected Recognition of Extraordinary Gain
日本化学工業 (the filing company)
1 listed security held by the company and 4 issues of shares contributed to its retirement benefit trust (the names of the issues have not been disclosed)
Improvement of capital efficiency and optimal allocation of management resources through the reduction of cross-shareholdings
Gain on the sale of investment securities of ¥4,000 million (the expected amount based on current share prices, to be recognized as an extraordinary gain). The sale price of the shares contributed to the retirement benefit trust is ¥6,000 million (expected amount), and the impact on consolidated results for the fiscal year ending March 2027 is immaterial.
Consolidated financial results for the fiscal year ending March 2027
For the impact on the consolidated earnings forecast for the fiscal year ending March 2027, please refer to the Notice Regarding Revisions to the Earnings Forecast disclosed today.
Related procedures
Filing of an extraordinary report
Kanto Local Finance Bureau (the filing destination for the extraordinary report)
The sales period will run from 12 August 2026 through the end of March 2027. The gain on the sale of investment securities of ¥4,000 million is scheduled to be recognized as an extraordinary gain in the consolidated financial results for the fiscal year ending March 2027. The funds generated from the sales will be used after taking into account the balance among growth investment, shareholder returns and financial soundness.
An extraordinary report is scheduled to be filed with the Kanto Local Finance Bureau.
| Item | Details |
|---|---|
| Event name | Sale of Cross-Shareholdings and Expected Recognition of Extraordinary Gain |
| Date of occurrence | 10 August 2026 (the date on which the Board of Directors resolved to proceed with the sales) |
| Subject Entity | 日本化学工業 (the filing company) |
| Target Locations / Products | 1 listed security held by the company and 4 issues of shares contributed to its retirement benefit trust (the names of the issues have not been disclosed) |
| Cause | Improvement of capital efficiency and optimal allocation of management resources through the reduction of cross-shareholdings |
| Amount of Impact on Business Performance | Gain on the sale of investment securities of ¥4,000 million (the expected amount based on current share prices, to be recognized as an extraordinary gain). The sale price of the shares contributed to the retirement benefit trust is ¥6,000 million (expected amount), and the impact on consolidated results for the fiscal year ending March 2027 is immaterial. |
| Accounting period in which recognized | Consolidated financial results for the fiscal year ending March 2027 |
| Impact on Earnings Forecast | For the impact on the consolidated earnings forecast for the fiscal year ending March 2027, please refer to the Notice Regarding Revisions to the Earnings Forecast disclosed today. |
| Type of litigation or proceeding | Filing of an extraordinary report |
| Court or authority | Kanto Local Finance Bureau (the filing destination for the extraordinary report) |
| Outlook | The sales period will run from 12 August 2026 through the end of March 2027. The gain on the sale of investment securities of ¥4,000 million is scheduled to be recognized as an extraordinary gain in the consolidated financial results for the fiscal year ending March 2027. The funds generated from the sales will be used after taking into account the balance among growth investment, shareholder returns and financial soundness. |
| Planned follow-up disclosure | An extraordinary report is scheduled to be filed with the Kanto Local Finance Bureau. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To improve capital efficiency and optimize the allocation of management resources by reducing cross-shareholdings. The proceeds from the sales will be used after taking into account the balance among growth investment, shareholder returns and financial soundness.